15348 Cutaneous squamous cell carcinoma in nonwhite individuals: A single-institution case-control study

The rate of new diagnosis of cutaneous squamous cell carcinoma (cSCC) is on the rise. This has led to a significant health and economic burden in the United States. Despite the fact that the United States population will be mostly non-white by 2050, little is known about how these cancers affect non-white individuals. The aim of our study was to define cSCC in the non-white population. A retrospective cohort study between non-white vs white was performed to identity the tumor characteristics, treatments, outcomes and survival of cSCC. This was a multicenter, single institutional study at Mayo Clinic (Arizona, Minnesota, and Florida). Subjects were identified in our retrospective database. The cohort consisted of 716 total patients, 99 non-white and 617 white. The age at biopsy or first treatment was earlier for non-white individuals compared with white individuals (67.7 [SD 15.2] vs 75.7 [SD 10.9]; P < .01). Non-white individuals were more likely to be immunosuppressed (26.5% vs 13%; P < .01). There was no statistical difference in the tumor location (including sun-exposed vs non–sun-exposed) or form of biopsy or treatment. After adjusting for age, the non-white group had a worse disease-free survival (Adj HR: 1.59, 95% CI 1.04-2.43, P = .04). In conclusion, nonwhite with cSCC were younger, immunosuppressed, and had a lower disease-free survival. With the increase in racial diversity within the U.S, more research needs to be done to identify the underlying cause of outcome differences between non-white and white individuals with cSCC.